


PHARMACEUTICAL 2021

FIVE PRIME THERAPEUTICS INC. Rank 116 of 409





PHARMACEUTICAL 2021

FIVE PRIME THERAPEUTICS INC. Rank 116 of 409

The relative strengths and weaknesses of FIVE PRIME THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIVE PRIME THERAPEUTICS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 139% points. The greatest weakness of FIVE PRIME THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is -1.2%, being 353% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	292,408
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,184
Liabilities, Non-Current	0
Other Assets	28,033
Other Compr. Net Income	-103
Other Expenses	-6,630
Other Liabilities	0
Other Net Income	1,912
Property and Equipment	11,209
Research and Development	65,491
Revenues	13,178
Selling, General and Administrative Expense	40,557

Output Variable	Value in 1000 USD
Assets	331,650
Liabilities	22,184
Expenses	99,418
Stockholders Equity	309,466
Net Income	-84,328
Comprehensive Net Income	-84,380
Economic Capital Ratio	-1.2%